What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
Voyager Therapeutics Inc (VGYR) has seen a modest 30% rise in its stock over the past year, but analysts predict a potential 250% surge in the next 12 months due to advancements in its drug programs. The company recently presented positive preclinical data for its Alzheimer's disease gene therapy, VY1706, which reduced tau protein in non-human primates by up to 64% without adverse events. Voyager plans to seek FDA authorization for human clinical trials of VY1706 in Q2 2026 and expects efficacy data for its VY7523 anti-tau antibody program in the latter half of the year.
Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings
Voyager Therapeutics' Principal Accounting Officer, Amy Quinlan, has filed an initial statement of beneficial ownership (Form 3), disclosing direct holdings of 36,749 common shares and two stock option awards covering a total of 78,500 shares. These options, granted under the company's 2015 and 2025 stock plans, vest over four years, aligning her interests with shareholders. The filing also details the vesting schedules and exercise prices of these equity awards.
EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman have each reported 0 shares and 0% beneficial ownership of Voyager Therapeutics, Inc. (NASDAQ: VYGR) common stock in a Schedule 13G/A amendment. This filing indicates that these entities and individuals disclaim membership in a group and beneficial ownership, except to the extent of pecuniary interest, and was signed on May 14, 2026. The amendment is characterized as an informational filing that does not suggest an active stake or control intent in Voyager.
Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares
An affiliate of Voyager Therapeutics (NASDAQ: VYGR) has filed a Form 144 to sell 9,406 shares of common stock, with the proposed transaction dated May 15, 2026. This filing is related to an option granted on February 6, 2026, and notes 60,421,287 shares outstanding as of May 15, 2026. The document also discloses a previous sale of 4,668 shares on February 24, 2026, which generated $17,588.09 in proceeds.
Voyager presents preclinical data for Alzheimer’s gene therapy
Voyager Therapeutics Inc. presented positive three-month toxicology data for VY1706, its tau-silencing gene therapy for Alzheimer's disease, showing it was well tolerated in non-human primates and reduced tau protein by up to 64%. The company is on track for an IND application in Q2 2026 and first-in-human dosing in H2 2026. Analysts have reiterated Buy ratings, citing significant upside potential and the company's strong financial position.
Voyager Therapeutics’ VY1706 Gene Therapy Shows Tau Reduction in Preclinical Models; Clinical Trial Expected in 2H 2026
Voyager Therapeutics announced positive preclinical data for their investigational gene therapy, VY1706, showing it reduced tau protein levels in preclinical models with a single intravenous dose and was well-tolerated. These findings support the continued development of VY1706 as a potential Alzheimer's treatment. The company anticipates initiating a clinical trial for the therapy in Alzheimer's disease in the second half of 2026.
One-time gene therapy cut Alzheimer’s tau up to 64% in monkeys
Voyager Therapeutics announced positive three-month GLP toxicology data for VY1706, an investigational tau-silencing gene therapy for Alzheimer's disease. A single intravenous dose of VY1706 was well tolerated in non-human primates and reduced tau protein by up to 64% in key brain regions. The company plans to submit its IND application in Q2 2026, with first-in-human dosing anticipated in the second half of 2026.
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well
Voyager Therapeutics presented positive three-month GLP toxicology data for its investigational Alzheimer’s disease gene therapy, VY1706, at the ASGCT 2026 Annual Meeting. The data showed VY1706 was well-tolerated and significantly reduced tau protein in key brain regions of non-human primates. Voyager plans to submit an IND application in Q2 2026 and expects to begin clinical trials in Alzheimer’s patients in H2 2026.
Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings
Voyager Therapeutics Inc. (VYGR) has disclosed significant risks in its latest SEC filings, specifically its Form 10-K for the year ended December 31, 2025. The company warned that various factors could negatively impact its business, financial condition, operating results, and long-term prospects. Despite these warnings, Wall Street maintains a "Strong Buy" consensus rating on VYGR stock.
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8
Wedbush has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained its price target of $8. This indicates the firm's continued positive outlook on the company's stock performance and valuation. The specific reasons for this maintained rating and price target are not provided in this brief update.
Voyager Therapeutics stock (US92916U1025): Q1 2026 results and pipeline updates drive sentiment
Voyager Therapeutics (Nasdaq: VYGR) reported its Q1 2026 financial and operating results, detailing progress in its neurology pipeline with a solid cash position despite ongoing losses. Key developments include the advancement of tau-silencing gene therapy VY1706 for Alzheimer’s disease, with an IND submission on track for Q2 2026, and NBIB-‘233, both expected to enter clinical trials in the second half of 2026. The company remains in a capital-intensive development phase, with future growth dependent on clinical milestones and regulatory success in the high-risk, high-reward CNS gene therapy sector.
Voyager Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Voyager Therapeutics, Inc. announced its earnings results for the first quarter ended March 31, 2026. The company reported a net loss of USD 27.94 million for the quarter, an improvement from USD 31.02 million in the same period last year. Basic and diluted loss per share from continuing operations were both USD 0.47, down from USD 0.53 a year ago.
Voyager Reports First Quarter 2026 Financial and Operating Results
Voyager Therapeutics reported its first quarter 2026 financial and operating results, highlighting a cash position of $172 million providing runway into 2028. The company is on track for first-in-human dosing of its tau silencing gene therapy VY1706 for Alzheimer's disease in H2 2026 and expects tau PET imaging data for its anti-tau antibody VY7523 in the same period. They also detailed pipeline advancements, collaboration updates, and upcoming milestones for 2026.
Voyager Therapeutics (Nasdaq: VYGR) posts Q1 2026 loss and advances tau drugs
Voyager Therapeutics reported a net loss of $27.9 million or $0.47 per share for Q1 2026, with collaboration revenue of $2.6 million. The company reduced operating expenses and ended the quarter with $171.7 million in cash, projecting a runway into 2028. Key pipeline advancements include VY1706 and NBIB-‘233 completing IND-enabling toxicology studies, with clinical entry expected in the second half of 2026, alongside anticipated third-party tau data and tau PET imaging results for VY7523 in late 2026.
Voyager Reports First Quarter 2026 Financial and Operating Results
Voyager Therapeutics reported its first quarter 2026 financial and operating results, highlighting a strong cash position of $172 million with a runway into 2028. The company is advancing its pipeline, including VY1706 for Alzheimer's disease with expected first-in-human dosing in H2 2026, and VY7523 with tau PET imaging efficacy data also anticipated in H2 2026. Neurocrine Biosciences is also moving forward with NBIB-‘223 for Friedreich’s ataxia, with a clinical trial planned for H2 2026 pending FDA clearance.
Alzheimer’s gene therapy moves toward human testing as cash lasts into 2028
Voyager Therapeutics reported its Q1 2026 financial and operating results, including a net loss of $27.9 million. The company announced key milestones toward human testing for its Alzheimer's gene therapy VY1706 and its anti-tau antibody VY7523, with first-in-human dosing expected in H2 2026 for VY1706 and tau PET imaging data for VY7523. Voyager maintains a strong cash position of $171.7 million, providing a runway into 2028 based on current plans.
Voyager Therapeutics: Q1 Earnings Snapshot
Voyager Therapeutics Inc. (VYGR) reported a first-quarter loss of $27.9 million, or 47 cents per share, which surpassed Wall Street expectations for a loss of 54 cents per share. However, the gene therapy company's revenue of $2.6 million fell short of analyst forecasts of $10 million. These financial results were generated using data from Zacks Investment Research.
Voyager Reports First Quarter 2026 Financial and Operating Results
Voyager Therapeutics reported its first-quarter 2026 financial and operating results, highlighting significant progress in its clinical pipeline for neurological diseases, including advancements in its tau silencing gene therapy VY1706 and anti-tau antibody VY7523. The company ended the quarter with a strong cash position of $172 million, providing a financial runway into 2028. Voyager anticipates key milestones in the second half of 2026, such as first-in-human dosing for VY1706 and tau PET imaging data for VY7523, reinforcing its commitment to addressing Alzheimer's disease and other neurological conditions.
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Voyager Therapeutics (NASDAQ:VYGR) is identified as a potentially risky investment due to its significant cash burn and declining revenue. The company had a cash runway of about 17 months as of December 2025, while its cash burn increased by 617% and operating revenue dropped by 50% in the last year, raising concerns about its future and the need for capital raising.
Voyager Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
Voyager Therapeutics Inc (VYGR) is projected to report a loss of 53 cents per share, according to this earnings preview. The article, sourced from Reuters via Refinitiv, provides a brief outlook on the company's anticipated financial performance.
Voyager Therapeutics (NasdaqGS:VYGR) Stock Forecast & Analyst Predictions
Voyager Therapeutics (NasdaqGS:VYGR) is forecast to see its earnings decline by 8.3% annually, while revenue is expected to grow by 8.2% per year. Analysts have maintained a consistent price target of $25.00 for the company, despite minor adjustments to various model inputs. Recent updates highlight leadership changes and the company's long-term value drivers, including its cash position, milestone potential, and advancing NeuroShuttle data.
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating for Voyager Therapeutics (VYGR) with a price target of $25.00. The company reported increased quarterly revenue but a GAAP net loss for the quarter ending December 31. Despite a "Strong Buy" analyst consensus, corporate insider sentiment on VYGR is negative, with recent share sales by the President & CEO.
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics (VYGR) with a $25.00 price target. This recommendation comes despite negative sentiment from corporate insiders in the last quarter, with the company reporting increased revenue but also a GAAP net loss in its latest earnings. Trucchio has a strong track record in the Healthcare sector, and the overall analyst consensus for VYGR is a Strong Buy.
[ARS] Voyager Therapeutics, Inc. SEC Filing
This article reports on an ARS SEC filing by Voyager Therapeutics, Inc. (VYGR) on April 28, 2026, accessible as a PDF document. It includes company stock data, recent news, and other SEC filings, indicating a neutral sentiment and low impact for this particular filing.
Voyager Therapeutics | DEF 14A: Definitive information statements
This article provides definitive information statements (DEF 14A) for Voyager Therapeutics. The content is presented as a document, suggesting it contains official filings or disclosures from the company.
Major share authorization increase on Voyager (VYGR) 2026 proxy agenda
Voyager Therapeutics will hold its 2026 virtual annual meeting on June 9, 2026, for stockholders of record as of April 13, 2026. Key agenda items include the election of three Class II directors, an advisory vote on executive compensation, ratification of Ernst & Young LLP as auditor, and a significant proposal to increase authorized capital stock from 125,000,000 to 245,000,000 shares, effectively doubling authorized common stock to 240,000,000 shares. The Board unanimously recommends voting "FOR" all proposals, emphasizing that the increase in authorized shares provides crucial flexibility for future equity financing, acquisitions, or incentive awards, without immediately issuing new shares.
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Voyager Therapeutics announced eight presentations at the ASGCT 2026 Annual Meeting, highlighting its IV-delivered CNS gene therapies. Key among these is a late-breaking presentation on VY1706, a tau-silencing gene therapy for Alzheimer’s disease, which demonstrated compelling pharmacology and safety in preclinical studies. The company is actively pursuing an IND application for VY1706 in Q2 2026, with projected first-in-human dosing in the latter half of the year.
Alzheimer’s gene therapy from Voyager lands late-breaker ASGCT slot
Voyager Therapeutics announced eight presentations at ASGCT 2026, highlighted by a late-breaking oral presentation for its IV-delivered tau-silencing gene therapy, VY1706, for Alzheimer's disease. The company reported compelling pharmacology and safety in a 3-month GLP toxicology study in non-human primates for VY1706, and anticipates submitting an IND in Q2 2026 to support first-in-human dosing in H2 2026. Additional presentations will cover advancements in TRACER capsid innovations, muscular/neuromuscular targeting, immune evasion, and manufacturing improvements.
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Voyager Therapeutics announced eight presentations at the ASGCT 2026 Annual Meeting, highlighting their IV-delivered CNS gene therapies. Key presentations include a late-breaking abstract on VY1706, a tau-silencing gene therapy for Alzheimer's disease, showing compelling pharmacology and safety in preclinical studies. The company is preparing to submit an IND application for VY1706 in Q2 2026 for projected first-in-human dosing in the second half of 2026.
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes
Voyager Therapeutics (VYGR) announced that CFO Nathan Jorgensen resigned, effective May 8, 2026, to pursue another opportunity. In response, the company appointed COO and CBO Robin Swartz as principal financial officer and treasurer, and Vice President of Finance Amy Quinlan as principal accounting officer, both effective the same date. While the leadership changes signal an orderly transition, TipRanks' AI Analyst Spark rates VYGR as Neutral, citing weakened financial performance and a loss-making valuation.
Voyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Above Fifty Day Moving Average - Here's Why
Voyager Therapeutics (NASDAQ:VYGR) stock recently crossed above its 50-day moving average, trading at $4.12 with analyst ratings presenting a "Moderate Buy" consensus and an average target price of $16.50. Despite beating Q1 EPS and revenue estimates, the company reported a deeply negative net margin, and analysts anticipate a negative EPS for the current year. Insider selling has been noted, while institutional investors show increased positions, indicating mixed market sentiment.
Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge
Voyager Therapeutics announced that its Chief Financial Officer, PeterাওHurlbut, is resigning effective May 17, 2024. Robin Swartz, the company's Chief Accounting Officer, will take over financial leadership responsibilities. Swartz has been with Voyager since 2021 and has extensive experience in finance and accounting within the life sciences sector.
Voyager Therapeutics Inc - Nathan Jorgensen Resigns As CFO Effective May 8, 2026
Voyager Therapeutics Inc. announced that its CFO, Nathan Jorgensen, will resign from his position, effective May 8, 2026. The announcement was made via a brief news item from Refinitiv.
Voyager Therapeutics (VYGR) outlines CFO exit and new finance leaders
Voyager Therapeutics announced that CFO Nathan Jorgensen will resign effective May 8, 2026, to pursue a new opportunity, with the company emphasizing no disagreement led to his departure. Robin Swartz, currently COO and CBO, will become principal financial officer and treasurer, and Amy Quinlan, VP of Finance, will become principal accounting officer, both effective the same date. This change represents a managed leadership transition with experienced internal successors.
Voyager Therapeutics, Inc. Announces Resignation of Nathan Jorgensen as Chief Financial Officer, Effective May 8, 2026
Voyager Therapeutics, Inc. announced the resignation of Nathan Jorgensen as Chief Financial Officer, effective May 8, 2026, as he pursues a new opportunity. Robin Swartz, who has served in various leadership roles at the company including Chief Operating Officer and Chief Business Officer, has been appointed to assume the role of principal financial officer, effective the same date. Ms. Swartz brings extensive experience from her long tenure at Genzyme Corporation and Sanofi Genzyme.
VYGR Stock Chart | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR)
This article provides the current stock chart and key financial data for Voyager Therapeutics Inc. (NASDAQ: VYGR). It lists the current stock price, its change, and offers various chart views and analytical sections for potential investors.
VYGR Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Voyager Therapeutics Inc. (VYGR) financials, focusing on its profitability and margins. VYGR boasts a 100.00% gross margin but shows negative operating and net margins, indicating challenges in converting operations into shareholder value. The company, with a market capitalization of $222.90M, is benchmarked against competitors like ENLV and CRDL, though their margin data is not provided for direct comparison.
Voyager Therapeutics (VYGR) asks shareholders to approve 245M authorized shares
Voyager Therapeutics is seeking shareholder approval to increase its authorized shares from 125,000,000 to 245,000,000 at its 2026 Annual Meeting. This increase, along with other proposals such as director elections and executive compensation advisory vote, aims to provide financial flexibility for future growth and capital-raising initiatives. The virtual meeting for stockholders will be held on June 9, 2026, with a record date of April 13, 2026.
VYGR PE Ratio & Valuation, Is VYGR Overvalued
This article assesses the valuation of Voyager Therapeutics Inc (VYGR), concluding that the stock is currently undervalued. Based on a relative valuation method, its fair price ranges from $4.94 to $6.54, compared to its current price of $3.96, indicating it is undervalued by 19.84%. The article also compares VYGR's P/B ratio, FCF yield, and P/S ratio against its historical averages and industry benchmarks, noting a robust revenue growth that supports its premium P/S ratio.
VYGR SEC Filings - Voyager Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Voyager Therapeutics Inc.'s (VYGR) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It details the company's financial results, corporate updates, pipeline progress in neurological diseases, and collaborations. The platform also offers AI-powered summaries to highlight key information from these regulatory disclosures.
Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $44,547.57 in Stock
Voyager Therapeutics CEO Alfred Sandrock sold 11,511 shares of company stock for $44,547.57 on April 2nd, reducing his ownership by 2.38%. This sale was part of a pre-arranged trading plan and follows earlier sales in February, bringing his year-to-date total to 37,900 shares sold. The company's stock is currently trading near $3.96, with analysts having an average "Moderate Buy" rating and a target price of $16.50.
Voyager Therapeutics (VYGR) CEO sells shares for RSU tax withholding
Voyager Therapeutics President and CEO Alfred Sandrock sold 11,511 shares of common stock at a weighted average price of $3.87 per share. This transaction was not a discretionary trade but occurred under a durable automatic sale instruction to cover tax withholding obligations on restricted stock units (RSUs) that vested on April 1, 2026. Following this sell-to-cover transaction, Sandrock directly holds 472,549 shares of Voyager Therapeutics common stock.
Voyager Therapeutics (VYGR) awards 50,000 RSUs to legal chief
Voyager Therapeutics (VYGR) has granted 50,000 restricted stock units (RSUs) to its SVP and General Counsel, Gregory L. Shiferman, as equity compensation. This award, valued at $0.00 per share, vests over three years, with one-third vesting annually, contingent on continuous service. Following this grant, Shiferman directly holds 50,000 shares/RSUs.
Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below 50-Day Moving Average - Should You Sell?
Voyager Therapeutics (NASDAQ:VYGR) stock has fallen below its 50-day moving average, trading at $3.96 with a 50-day moving average of $3.92. Despite this technical pullback, analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.50, and institutional investors have increased their positions. Recent insider selling by CEO Alfred Sandrock, however, adds a mixed signal to the company's financial overview, which includes beating Q2 earnings estimates but showing negative net margins and return on equity.
VYGR SEC Filings - Voyager Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Voyager Therapeutics Inc.'s (VYGR) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. It highlights the company's biotechnology focus on neurological diseases, detailing financial figures, pipeline progress (including Alzheimer's programs), and collaboration agreements. The platform also offers AI-powered summaries to help investors quickly parse key information from these regulatory documents.
Voyager Therapeutics (VYGR) price target increased by 12.22% to 17.17
This article reports that the price target for Voyager Therapeutics (VYGR) has been increased by 12.22%, moving it to a new target of $17.17.
Vanguard disaggregates holdings after realignment (VYGR) — reports 0% ownership
Vanguard has filed an amended Schedule 13G/A for Voyager Therapeutics Inc. (VYGR) indicating 0% beneficial ownership and 0 shares. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. The filing clarifies that this is an administrative reporting change and not a sale or increase in ownership.
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Strong-Buy at Truist Financial
Truist Financial has upgraded Voyager Therapeutics (NASDAQ:VYGR) to a "strong-buy" rating, citing recent positive news including a deal that caused a significant stock price increase. Despite beating quarterly earnings and revenue estimates, the company remains unprofitable with a negative net margin. The upgrade contributes to a mixed analyst consensus, with an average target price of $16.50.
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut
Voyager Therapeutics CEO Al Sandrock declared 2026 the "year of tau," highlighting progress in two tau-directed programs: an antibody and an siRNA-based gene therapy. The company anticipates clinical deployment of its BBB-penetrant capsids in 2026 and plans to share data on a "brain shuttle" platform. Voyager continues to leverage partnerships with Neurocrine, Novartis, and AstraZeneca, retaining potential U.S. opt-in rights and royalties.
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11
Citi has reiterated its Buy rating for Voyager Therapeutics (VYGR.US), maintaining a target price of $11. This indicates a continued positive outlook from the firm regarding the company's stock performance.
